Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health
Transaction subject to Wesana shareholder approval and expected to close in Q2 2023SANA-013 combination of psilocybin and CBD being developed for potential...
Brain
Cerevance Announces Presentations at Two Medicinal Chemistry Conferences
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by Fundamental Research Corp. with a “Buy” Recommendation
Providence, RI, March 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation...
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau),...
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Equity Analyst Coverage by EF Hutton with a “Buy” Recommendation
Providence, RI, March 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation...
Healthy Directions Partners with Dr. Kulreet Chaudhary to Combine the Tradition Of Ayurvedic Practice with Modern-Day Science
Dr. Kulreet Chaudhary Partners with Healthy Directions Neurologist and Ayurvedic practitioner, Dr. Kulreet Chaudhary has developed Prajna Ayurveda herbals with...
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
OV329 Phase 1 trial is progressing on trackAn IV formulation candidate suitable for future clinical trials has been achieved for...
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE...
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-- Full results from ELPIS I trial published in European Heart Journal Open – -- First patient to be randomized...
Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder
Illustration 1: Effect of anti-CHI3L1 on Primary Lung Cancer Illustration 2: Effect of bi-specific antibody on Glioblastoma tumorsProvidence, RI, March...
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks...
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal...
Cerevance Announces Upcoming Presentation at the Alzheimer’s Research UK Conference 2023
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on March 21, 2023
GUILFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the...
Relievant Medsystems Announces Positive Local Coverage Determination by Palmetto GBA for Basivertebral Nerve Ablation in Treating Chronic Vertebrogenic Low Back Pain
MINNEAPOLIS, March 06, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease...
Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...